The end of the Spring Festival stock market is over，Guangzhou Pharmaceutical (600332) and Baiyunshan A (000522), a subsidiary of Guangyao Group, continue to maintain a suspension status。January 30，Guangzhou Pharmaceutical (600332) disclosed the progress of major asset reorganization，Calculating the company's controlling shareholder Guangzhou Pharmaceutical Group Co., Ltd. has obtained My stake betting appthe stake online sports bettingpre -checking of the Guangdong SASAC on the major asset reorganization items，Company and related parties will continue to promote this major asset reorganization items，Research Plan，Consultation with relevant departments。

but but，Its "warm -up action" has not stopped。Just in January，Guangyi Group announced the establishment of the Guangzhou Medical Research Council，and hire the 1998 Nobel Nobel Prize winner、The father of "Viagra"、Dr. Fried-Murad, an academician of the Chinese Academy of Sciences, served as the dean of the General Hospital of Guangyao，Appointment of the Chinese Academy of Engineering、Academician Zhong Nanshan, president of the Chinese Medical Association, serves as the honorary dean of Guangzhou Medical Research Institute。

Some people related to Guangyao revealed，Guangyao Group will cooperate with Murad and its team，If you buy its existing new drug research results，or the establishment of a joint venture company and other joint development of new drugs。Murad also said at the appointment ceremony，It will be mainly engaged in the development of Chinese herbal medicine at the hire period。

It is understood，2011 Cantonese Pharmaceutical Stake Sports BettingGroup'My stake betting apps rapid development momentum，Complete industrial and commercial sales revenue of 33.08 billion yuan for the whole year，increased by 19.9%year -on -year; the total profit was 1.35 billion yuan，increased by 31.51%year -on -year。In view of the Guangyao Group's "Twelfth Five -Year Plan" development strategy and planning, "the sales revenue of industrial and commercial sales at the end of maturity reached 60 billion yuan、Create the development goals of becoming a strategic emerging industry leading enterprise，The Guangzhou Medical Research Council of this physical operation，There is a chemical drug research branch、Biomedical Research Branch、Chinese Medicine and Natural Drug Research Branch、Big Health Product Research Branch and New Pharmaceutical R & D Public Service Innovation Platform，aimed at further implementation of science and technology integrated operation and "11x" development model，Provide technical support for its "Twelfth Five -Year Plan" target。

Representation of Guangyao Group，Since then, it plans to apply the Nobel Prize and other aspects to the maximum medical technology innovation in Guangzhou、Industrial common technology、stake betting appKey Technology、stake online sports bettingResearch tasks and major scientific research projects developed by important products。I hope to introduce world -class scientific and technological innovation teams，R & D for its new drugs、Technical progress、Development plan provides guidance、Help，To improve the international influence of the technological innovation of Guangyao Group，Let Guang Pharmaceutical Group develop into a world -renowned pharmaceutical company group and strategic emerging industry leading enterprise。

The Guangzhou Pharmaceutical "Dannan Pharmaceutical" Innovation Fund with a capital pool of 100 million yuan also started at the same time as the Guangzhou Medical Research Institute，It is used to promote the large project of Guangyao Group、R & D of big varieties。Li Chuyuan, general manager of Guangyao Group, said，Nobel General Dr. Murad and his technical team joined，Not only is it conducive to shortening the gap between Guangyao Group，Expand the influence of international，It is more conducive to creating Guangye Pharmaceutical General Hospital into the first domestic R & D platform in China，Make more traditional Chinese medicine products internationally become reality。